In the search for new clinically applicable parame-determination becomes in this way specific for ters for the prenatal assessment of fetal maturity, pyruvate kinase. we examined the pyruvate kinase activity in Seventy-three amniotic fluid samples were examamniotic fluid samples. The enzyme was dis-ined (Tab. I); they contained neither meconium covered in the thirties by LOHMANN and MEYER-nor blood. Amniotic fluid was obtained by trans-HOF [2, 4]. Pyruvate kinase [PK] (ATP: pyruvate abdominal ultrasound-directed amniocentesis. At 2-O-phosphotransferase, E.G. 2.7.1.40) transfers term (37-42 weeks of gestation) the fluid was the energy-rich phosphate bond of phosphoenol-obtained by transcervical amniocentesis at the pyruvate to ADP under formation of ATP and onset of labor. Since PK in vitro is labile, the sampyruvate. As an enzyme of glycolysis PK is chiefly pies were centrifuged at 2° to 4°C immediately present in the cytoplasma.
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after withdrawal, and the supernatant was subWe measured PK activity in a reaction coupled sequently processed. with lactate dehydrogenase by the decrease of During the second trimester and up to the 33rd NADH absorbance per time interval, whereby the gestational week, we could only measure slight PK converted quantity of phosphoenolpyruvate or activities in amniotic fluid. In half of the cases no pyruvate and the NADH decrease are synchronized PK activity was detectable at all. From the 34th [1] . Interfering glycolytic metabolites are elimi-week to the 36th week of gestation a discrete PK nated prior to the PK reaction; the reaction com-increase was observed; the maximal level recorded mences only after addition of ADP solution. The was below 7 U/L. No PK activity was found in 20 meconium-stained amniotic fluid samples. Addition of meconium to amniotic fluid samples with previously present PK activity led to a disappearance of the enzyme activity.
The first postnatal urine from newborns contained no PK or only a trace of the enzyme. The pyruvate kinase activity in amniotic fluid and that in the plasma of umbilical vpnous blood of the same neonates did not correlate. Supplementary studies on the origin of the enzyme in amniotic fluid produced in essence the following results. By means of artificial in vitro cytolysis in amniotic fluid sediments, additional PK activity could be liberated. Considerable PK activity was detectable in tracheal secretions of therapeutically intubated newborn infants. Thus, the presumable main sources of the enzyme in amniotic fluid are the epithelium cells of the skint he respiratory tract and the amnion [3] . According to the results of this pilot study and particularly in view of the rapid PK rise "at term", assay of amniotic fluid pyruvate kinase appears to be of clinical importance as an additional indicator of fetal maturity in the perinatal period.
Summary
During the second and third trimesters increasing activities of the glycolytic enzyme pyruvate kinase are to be found in human amniotic fluid. At term (37 to 42 weeks), a very steep rise in amniotic fluid pyruvate kinase can be noticed, which may serve as an additional prenatal indicator of fetal maturity.
The presumable main sources of the enzyme in amniotic fluid are the epithelium cells of the skin, the respiratory tract and the amnion. In meconium stained amniotic fluid no pyruvate kinase activity is detectable. Addition of meconium to amniotic fluid samples with previously present pyruvate kinase activity leads to a disappearance of the enzyme activity. 
